Carrying short-acting nitrates is not a contra-indication to the use of PDE5 inhibitors.
D015106:3',5'-Cyclic-GMP Phosphodiesterases; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000201:enzymology; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006801:Humans; D008131:London; D009566:Nitrates / Q000627:therapeutic use*; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000187:drug effects; D016896:Treatment Outcome
D009566:Nitrates; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; C517381:PDE5A protein, human